3.8 Article

OCT biomarkers as predictors of visual improvement in diabetic macular edema eyes receiving dexamethasone implants

Related references

Note: Only part of the references are listed.
Article Ophthalmology

Time to Resolution of Diabetic Macular Edema after Treatment with Intravitreal Aflibercept Injection or Laser in VISTA and VIVID

Carolina C. S. Valentim et al.

Summary: This study assessed the relationship between baseline factors and time to diabetic macular edema (DME) resolution. The results showed that intravitreal aflibercept injection (IAI) treatment had a higher resolution rate and longer resolution time for DME compared to laser control.

OPHTHALMOLOGY RETINA (2023)

Review Ophthalmology

Diabetic retinopathy, oxidative stress, and sirtuins: an in depth look in enzymatic patterns and new therapeutic horizons

Marcella Nebbioso et al.

Summary: Diabetic retinopathy is a major cause of blindness in the world, with complex interactions involving inflammation, oxidative stress, and SIRTs pathways. SIRTs play a crucial role in regulating inflammatory responses, insulin sensitivity, and metabolic processes in DR, making them a potential target for novel therapeutic approaches.

SURVEY OF OPHTHALMOLOGY (2022)

Review Biochemistry & Molecular Biology

The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers

Marion R. Munk et al.

Summary: This paper summarizes predictive biomarkers in DME to assist in identifying patients who may benefit from primary dexamethasone treatment or an early switch in treatment. These markers provide valuable guidance for individual treatment decisions in DME.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Review Health Care Sciences & Services

Indicators of Visual Prognosis in Diabetic Macular Oedema

Sagnik Sen et al.

Summary: The review evaluated the relative importance of each risk factor in visual prognostication of diabetic macular oedema (DMO) eyes post-treatment and emphasized the significance of phenotypes formed by combining these factors in predicting visual outcomes. The development of stratification based on these phenotypes for personalized medicine in DMO treatment was proposed.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Review Endocrinology & Metabolism

Optical Coherence Tomography (Angiography) Biomarkers in the Assessment and Monitoring of Diabetic Macular Edema

Corina-Iuliana Suciu et al.

JOURNAL OF DIABETES RESEARCH (2020)

Article Ophthalmology

Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers

Vincenza Bonfiglio et al.

ACTA OPHTHALMOLOGICA (2019)

Review Ophthalmology

Diabetic macular edema: Evidence-based management

David J. Browning et al.

INDIAN JOURNAL OF OPHTHALMOLOGY (2018)

Review Ophthalmology

Diabetic Macular Edema: Current Understanding, Pharmacologic Treatment Options, and Developing Therapies

Kevin Miller et al.

ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY (2018)

Article Neurosciences

The pathology associated with diabetic retinopathy

Judith Lechner et al.

VISION RESEARCH (2017)

Review Public, Environmental & Occupational Health

Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis

Seth R. Flaxman et al.

LANCET GLOBAL HEALTH (2017)

Article Ophthalmology

Functional and Anatomical Outcomes in Patients With Serous Retinal Detachment in Diabetic Macular Edema Treated With Ranibizumab

Audrey Giocanti-Auregan et al.

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2017)

Article Ophthalmology

VISUAL AND MORPHOLOGIC OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR DIABETIC MACULAR EDEMA BASED ON OPTICAL COHERENCE TOMOGRAPHY PATTERNS

Kyung Hoon Seo et al.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)

Review Ophthalmology

Dexamethasone intravitreal implant in the treatment of diabetic macular edema

Pravin U. Dugel et al.

CLINICAL OPHTHALMOLOGY (2015)

Article Pharmacology & Pharmacy

Dexamethasone-loaded poly(ε-caprolactone) intravitreal implants:: A pilot study

Silvia Ligorio Fialho et al.

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2008)